Genetic polymorphism analysis of cytochrome P4502E1 (CYP2E1) in Chinese Han populations from four different geographic areas of Mainland China

Genomics

Volumn 95, Issue 4, 2010, Pages 224-229

  Tang, Kefu ^a,b   Li, Xin ^a,b   Xing, Qinghe ^c   Li, Weidong ^a   Feng, Guoyin ^d   He, Lin ^a,c   Qin, Shengying ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c FUDAN UNIVERSITY   (China)

^d SHANGHAI MENTAL HEALTH CENTER   (China)

Author keywords

Chinese mainland; CYP2E1; Haplotype; Polymorphism

Indexed keywords

CYTOCHROME P450 2E1; XENOBIOTIC AGENT;

ARTICLE; CHINA; CHINESE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ETHNIC DIFFERENCE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HAPLOTYPE; HUMAN; MUTATION RATE; NONSENSE MUTATION; NORMAL HUMAN; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CODON, NONSENSE; CYTOCHROME P-450 CYP2E1; FEMALE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 77950310834     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2010.01.005     Document Type: Article

References (35)

1. Lieber C.S. Cytochrome P-4502E1: its physiological and pathological role. Physiol. Rev. 1997, 77:517-544.
2. Hasler J.A. Pharmacogenetics of cytochromes P450. Mol. Aspects Med. 1999, 20:12-137.
3. Peter R., Böker R., Beaune P.H., Iwasaki M., Guengerich F.P., Yang C.S. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIEI. Chem. Res. Toxicol. 1990, 3:566-573.
4. Guengerich F.P., Kim D.H., Iwasaki M. Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 1991, 4:168-179.
5. Kharasch E.D., Thummel K.E. Identification of cytochrome P4502E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiologist 1993, 79:795-807.
6. Bolt H.M., Roos P.H., Thier R. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. Int. Arch. Occup. Environ. Health 2003, 76:174-185.
7. Hu Y., Hakkola J., Oscarson M., Ingelman-Sundberg M. Structural and functional characterization of the 5'-flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene. Biochem. Biophys. Res. Commun. 1999, 263:286-293.
8. McCarver D.G., Byun R., Hines R.N., Hichme M., Wegenek W. A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol. Appl. Pharmacol. 1998, 152:276-281.
9. Itoga S., Nomura F., Makino Y., Tomonaga T., Shimada H., Ochiai T., et al. Tandem repeat polymorphism of the CYP2E1 gene: an association study with esophageal cancer and lung cancer. Alcohol., Clin. Exp. Res. 2002, 26:15S-19S.
10. Le Marchand L., Donlon T., Seifried A., Wilkens L.R. Red meat intake, CYP2E1 genetic polymorphisms, and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 2002, 11:1019-1024.
11. Uematsu F., Kikuchi H., Motomiya M., Abe T., Sagami I., Ohmachi T., Wakui A. Association between restriction fragment length polymorphism of the human cytochrome P450 2E1 gene and susceptibility to lung cancer. Jpn. J. Cancer Res. 1991, 82:254-256.
12. Haufroid V., Buchet J.P., Gardinal S., Lison D. Cytochrome P4502E1 phenotyping and the measurement of the chlorzoxazone metabolic ratio: assessment of its usefulness in workers exposed to styrene. Int. Arch. Occup. Environ. Health 2002, 75:453-458.
13. Vodicka P., Soucek P., Tates A.D., Dusinska M., Sarmanova J., Zamecnikova M., Vodickova L., Koskinen M., Zwart F.A., Natajaran A.T., Hemminki K. Association between genetic polymorphisms and biomarkers in styrene-exposed workers. Mutat. Res. 2001, 482:89-103.
14. Garte S., Gaspari L., Alexandrie A.K., Ambrosone C., Autrup H., Autrup J.I., Baranova H., Bathum L., Benhamou S., BoVetta P., Bouchardy C., Breskvar K., Brockmöller J., Cascorbi I., Clapper M.L., Coutelle C., Daly A., Dell'Omo M., Dolzana V., Dresler C.M., Fryer A., Haugen A., Hein D.W., Hildesheim A., Hirvonen A., Hsich L.L., Ingelman-Sundberg M., Kalina I., Kang D., Kihara M., Kiyohara C., Kremers P., Lazarus P., Le Marchand L., Lechner M.C., Lieshout E.M.M., London S., Manni J.J., Maugard C.M., Morita S., NazarStewart V., Noda K., Oda Y., Parl F.F., Pastorelli R., Persson I., Peters W.H.M., Rannug A., Rebbeck T., Risch A., Roelandt L., Romkes M., Ryberg D., Salagovic J., Schoket B., Seidegard J., Shileds P.G., Sim E., Sinhet D., Strange R.C., Stücker I., Sugimura H., To-Figueras J., Vineis P., Yu M.C., Taioli E. Metabolic gene polymorphism Frequencies in control populations. Cancer Epidemiol. Biomark. Prev. 2001, 10:1239-1248.
15. Madison L., Hoar L.D., Holroyd C.D. DNA banking: the effect of storage of blood and isolated DNA on integrity of DNA. Am. J. Med. Genet. 1987, 27:379-382.
16. Itoga S., Harada S., Nomura F. Polymorphism of the 5'-flanking region of the CYP2E1 gene: an association study with alcoholism. Alcohol., Clin. Exp. Res. 2001, 25:11S-15S.
17. Howard L.A., Ahluwalia J., Lin S.K., Sellers E.M., Tyndale R.F. CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. Pharmacogenetics 2003, 13:321-328.
18. Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Vainio H. The human CYP2E1 gene and lung cancer: Dral and Rsal restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 1993, 14:85-88.
19. Plee-Gautier E., Foresto F., Ferrara R., Bodenez P., Simon B., Manno M., et al. Genetic repeat polymorphism in the regulating region of CYP2E1: frequency and relationship with enzymatic activity in alcoholics. Alcohol., Clin. Exp. Res. 2001, 25:800-804.
20. Lee H.C., Lee H.S., Jung S.H., et al. Association between polymorphisms of ethanol-metabolizing enzymes and susceptibility to alcoholic cirrhosis in a Korean male population. J. Korean Med. Sci. 2001, 16:745-750.
21. Kongruttanachok N., Sukdikul S., Setavarin S., et al. Cytochrome P450 2E1 polymorphism and nasopharyngeal carcinoma development in Thailand: a correlative study. BMC Cancer 2001, 1:4.
22. Watanabe J., Hayashi S.I., Nakachi K., et al. Pst I and Rsa I RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucleic Acids Res. 1990, 18:7194.
23. Stephens E.A., Taylor J.A., Kaplan N., et al. Ethnic variation in the CYP2E1 gene, polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 1994, 4:185-192.
24. Pastorelli R., Bardazzi G., Saieva C., et al. Genetic determinants of alcohol addiction and metabolism: a survey in Italy. Alcohol., Clin. Exp. Res. 2001, 25:221-227.
25. Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Vainio H. The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 1993, 14:85-88.
26. Omer B., Ozbek U., Akkose A., Kilic G. Genetic polymorphism of cytochrome P450 2E1 in the Turkish population. Cell Biochem. Funct. 2001, 19:273-275.
27. Griese E.U., Llett K.F., Kittringham N.R., et al. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia. Pharmacogenetics 2001, 11:69-76.
28. Sarmanova J., Tynkova L., Sosuva S., Gut I., Soucek P. Genetic polymorphisms of biotransformation enzymes: allele frequencies in the population of the Czech Republic. Pharmacogenetics 2000, 10:781-788.
29. Persson I., Johansson I., Berlimng H., et al. Genetic polymorphism of cytochrome P450IIE1 in a Swedish population: relationship to incidence of lung cancer. FEBS Lett. 1993, 319:207-211.
30. Fairbrother A., Grove J., de Waziers I., Steimel D.T., Day C.D., Crespi C.L., Daly A.K. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 1998, 8:543-552.
31. Neuhaus T., Ko Y.D., Lorenzen K., Fronhoffs S., Harth V., Bröde P., Vetter H., Bolt H.M., Pesch B., Brüning T. Association of cytochrome P450 2E1 Polymorphisms and head and neck squamous cell cancer. Toxicol. Lett. 2004, 151:273-282.
32. Ernstgard L., Warholm M., Johanson G. Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity. Br. J. Clin. Pharmacol. 2004, 58(2):190-200.
33. Ulusoy G., Arinç E., Adali O. Genotype and allele frequencies of polymorphic CYP2E1 in the Turkish population. Arch. Toxicol. 2007, 81:711-718.
34. Yang B.M., O'Reilly D.A., Demaine A.G., Kingsnorth A.N. Study of polymorphisms in the CYP2E1 gene in patients with alcoholic pancreatitis. Alcohol 2001, 23:91-97.
35. Wang H.-H., Liao Y.-W., Chiang H.-L., Wu J.-Y., Chen Y.-T. Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population. Pharmacogenomics 2009, 10(3):359-374.